TI
CSTL icon

tru Independence’s Castle Biosciences CSTL Stock Holding History

tru Independence’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-370
Closed -$14 – 434
2020
Q2 		$14 Sell
370
-85
-19% -$2.9K ﹤0.01% 550
2020
Q1 		$14 Hold
455
– – ﹤0.01% 403
2019
Q4 		$14K Buy
+455
New +$11.1K ﹤0.01% 521

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

tru Independence's CSTL Position: Q3 2020 in Review

tru Independence sold out of Castle Biosciences (CSTL) in Q3 2020, closing a stake of 370 shares — an estimated $14 sold.

tru Independence first reported a position in CSTL in Q4 2019 and held it in 3 quarters. The position peaked at $14K in Q4 2019. 144 funds tracked by Wall St. Rank hold CSTL as of Q3 2020.

  • tru Independence reported no remaining Castle Biosciences position as of Q3 2020 after selling out during the quarter.
  • tru Independence sold 370 Castle Biosciences shares in Q3 2020, an estimated $14.
  • tru Independence first reported a position in Castle Biosciences in Q4 2019 and held it in 3 quarters.
  • tru Independence's Castle Biosciences position peaked at $14K in Q4 2019.
  • 144 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.